


FIG. I






FIG. 3




FIGURE 5

PROTECTION OF DOGS AGAINST COPV INFECTION BY THE PASSIVE TRANSFER OF IMMUNOGLOBULIN

TREATMENT PROCEDURE	Number of dogs with tumors	Number of dogs
Infused with lactate Ringers solution	4	4
Infused with non-immune dog serum, 200 mg/kg	4	4
Infused with immune dog serum, 200 mg/kg	0	4

J


FIGURE 6

DOG VACCINATION STUDIES UTILIZING CONFORMATIONALLY-CORRECT L1 PROTEIN PURIFIED FROM RECOMBINANT-BACULOVIRUS INFECTED Sf9 CELLS

Vaccination Procedure	#dogs with oral tumors
Buffer	6/8
Formaline-fixed wart extract	0/8
L1	0/8
L1 + alum adjuvant	0/8
L1 + QS21 adjuvant	0/8

4/6/94: Coating Ag-isolated COPV particles. Dog sera: 1:100 dilutions of pooled (n-8) samples. KGP 2° (anti-igg) at 1:200, Rabbit sera at 1:500, KGP 2° at 1:1000. 30 minute reading Normal Rabbit serum was 0.080. Exp. COPV#1:L1 VLP

...)



4/6/94: Coating Ag=Recombinant L1(insoluble). Dog sera: 1:100 dilutions of pooled (n=8) samples. Bethyl 2° (anti-igG) at 1:500. Rabbit sera at 1:500, KGP 2° at 1:1000. 30 minute reading Normal Rabbit serum was 0.080. Exp. COPV#1:L1 VLP

